Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIOLA trial of olaparib in advanced HER2-negative breast cancer selected by homologous recombination deficiency biomarkers
2021-001398-22Phase 2Active
- Sponsor
- SOLTI
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in breast cancer, triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer, sponsored by SOLTI. Primary endpoint: Overall response rate. Started Nov 2021; status: active.
02
Drugs
olaparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on 2021-001398-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001398-22.